FEATURED COMPANIES
- BGI
- Dolomite Bio
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- Illumina, Inc.
- Lexogen GmbH
- MORE
Key Questions Answered in this Report:
- What are the major market drivers, restraining factors, and opportunities in the global RNA sequencing market?
- What are the underlying structures resulting in the emerging trends within the global RNA sequencing market?
- What are the key development strategies which are incorporated by the major players in order to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for RNA sequencing?
- What are the key patents obtained by the companies for various technologies in the global RNA sequencing market?
- How each segment of the market is anticipated to grow during the forecast period 2019 to 2028 and what is the estimated revenue to be generated by each of the segments on the basis of:
- product type, including types of instruments, reagents, and kits, and software
- technology, including, single-molecule-based sequencing, sequence by synthesis technology, nanopore sequencing technology, and ion torrent sequencing technology
- workflow, including sample enrichment, nucleic acid isolation and extraction, library preparation, sequencing, and data analysis and management
- end-user, including biopharmaceuticals, life science and biotechnology companies, diagnostic centers, and research and academia
- applications, including drug discovery, translational medicine, diagnostics, and others
- region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World
- Who are the leading players with significant offerings to the global RNA sequencing market? What is the anticipated market dominance for each of these leading players?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the challenges in the global RNA sequencing market currently?
The RNA sequencing industry analysis projects the market to grow at a significant CAGR of 14.21% during the forecast period, 2019-2028. The RNA sequencing market generated $1,064.6 million in revenue in 2019, in terms of value. The RNA sequencing market growth has been primarily attributed to the major drivers in this market, such as an increase in adoption of personalized medicine, increased utility in patient stratification and therapeutic response research, and significant external funding for executing research and development. However, the expected implementation of patient protection and affordable care act in the U.S., existing lawsuits, and lack of approval with uncertain reimbursement and regulatory policies, among others, are restraining market growth.
Expert Quote
“We are proud to continue our tradition of driving down the cost of sequencing without compromising accuracy. Products are designed to enable core labs, small to medium research labs, and clinical facilities to access high-intensity sequencing applications using our industry-leading SBS technology.”
Scope of the Market Intelligence on RNA sequencing Market
The RNA sequencing research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers. In addition, the study also includes exhaustive information on the challenges, opportunities, perception of the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global RNA sequencing market.
Market Segmentation
- The RNA sequencing market (on the basis of the manufacturer) is segmented into product, technology, workflow, end-user, application, and region.
- The RNA sequencing market (on the basis of product) is segmented into instruments, reagents and kits, and software.
- The RNA sequencing market (on the basis of technology) is segmented into single molecule-based sequencing, sequence by synthesis technology, nanopore sequencing technology, and ion torrent semiconductor sequencing.
- The RNA sequencing market (on the basis of workflow) is segmented into sample enrichment, nucleic acid isolation and extraction, library preparation, sequencing, and data analysis and management.
- The RNA sequencing market (on the basis of end-user) is segmented into biopharmaceuticals, life-sciences and biotechnology companies, diagnostic centers, and research and academia.
- The RNA sequencing market (on the basis of application) is segmented into drug discovery, translational medicine, diagnostics, and others.
Key Companies in the RNA Sequencing Market
The key manufacturers who have been contributing significantly to the RNA sequencing market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BGI, F. Hoffmann La-Roche AG, Fluidigm Corporation, Illumina, Inc., Lexogen GmbH, Oxford Nanopore Technologies, Pacific Biosciences, QIAGEN N.V., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Dolomite Bio, Takara Bio Inc., and Merck KGaA., among others.
FEATURED COMPANIES
- BGI
- Dolomite Bio
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- Illumina, Inc.
- Lexogen GmbH
- MORE
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global RNA Sequencing Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 RNA Sequencing: Overview
4.1 Current State of RNA Sequencing
4.2 Market Footprint and Future Potential
4.2.1 North America
4.2.1.1 Future Potential
4.2.2 Europe
4.2.2.1 Future Potential
4.2.3 Asia-Pacific
4.2.3.1 Future Potential
4.2.4 Latin America
4.2.4.1 Future Potential
4.2.5 Rest-of-the-World
4.2.5.1 Future Potential
4.3 Technology Assessment
4.4 Commercialized Platforms and Applications
5 Industry Analysis
5.1 Legal and Regulatory Framework
5.1.1 U.S.
5.1.1.1 Guidelines Published in FY2018
5.1.1.2 Guidelines Published in FY2016
5.1.2 Europe
5.1.3 Japan
5.2 Patent Landscape
5.3 Comparison of RNA Sequencing Costs
5.4 Publication Statistics
6 Global RNA Sequencing Market: Market Dynamics
6.1 Overview
6.2 Impact Analysis of Market Dynamics
6.3 Market Drivers
6.3.1 Increase in Adoption of Personalized Medicine due to Decrease in Cost of Sequencing
6.3.2 Increased Utility in Predictive Biomarkers and Therapeutic Response Research
6.3.3 Significant External Funding for Executing Research and Development
6.4 Market Restraints
6.4.1 Expected Implementation of the Patient Protection and Affordable Care Act in the U.S
6.4.2 Existing Lawsuits
6.4.3 High Capital Requirement Hampering the Expansion of Global Reach
6.5 Market Opportunities
6.5.1 Development of Portable and Cost-Efficient Technologies
6.5.2 Hybridization of Technologies
7 Competitive Landscape
7.1 Key Strategies and Developments
7.1.1 Product Launch and Upgradations
7.1.2 Synergistic Activities
7.1.3 Funding and Expansions
7.1.4 Mergers and Acquisitions
7.1.5 Product Approvals
7.2 Market Share Analysis
7.3 Growth Share Analysis (by Companies), 2018
8 Global RNA Sequencing Market (by Product Type)
8.1 Overview
8.2 Instruments
8.2.1 Fully Automated Systems
8.2.2 Semi-Automated Instruments
8.3 Reagents and Kits
8.3.1 Sample Enrichment
8.3.2 Sample Isolation and Extraction
8.3.3 Library Preparation
8.3.4 Sequencing
8.4 Software
9 Global RNA Sequencing Market (by Technology), 2018-2028
9.1 Overview
9.2 Single Molecule Based Sequencing
9.3 Sequence by Synthesis Technology
9.4 Nanopore Sequencing Technology
9.5 Ion Torrent Semiconductor Sequencing
10 Global RNA Sequencing Market (by Workflow), 2018-2028
10.1 Overview
10.2 Sample Isolation and Extraction
10.2.1 Market Size and Future Potential
10.3 Sample Enrichment
10.3.1 Market Size and Future Potential
10.4 Library Preparation
10.4.1 Market Size and Future Potential
10.5 Sequencing
10.5.1 Market Size and Future Potential
10.6 Data Analysis and Management
10.6.1 Market Size and Future Potential
11 Global RNA Sequencing Market (by End User), 2018-2028
11.1 Overview
11.2 Biopharmaceuticals
11.3 Diagnostic Centers
11.4 Life-sciences and Biotechnology Companies
11.5 Research and Academia
12 Global RNA Sequencing Market (by Application), 2018-2028
12.1 Overview
12.2 Diagnostics
12.2.1 Market Size and Future Potential
12.3 Drug Discovery
12.3.1 Market Size and Future Potential
12.4 Translational Medicine
12.4.1 Market Size and Future Potential
12.5 Others
13 Global RNA Sequencing Market, by Region
13.1 Overview
13.2 North America
13.2.1 Key Dynamics
13.2.2 Competitive Landscape
13.2.3 U.S.
13.2.3.1 Market Size and Growth Potential
13.2.3.2 New Market Opportunities
13.2.3.3 Unmet Needs
13.2.4 Canada
13.2.4.1 Market Size and Growth Potential
13.2.4.2 New Market Opportunities
13.2.4.3 Unmet Needs
13.3 Europe
13.3.1 Key Dynamics
13.3.2 Competitive Landscape
13.3.3 Germany
13.3.3.1 Market Size and Growth Potential
13.3.3.2 New Market Opportunities
13.3.3.3 Unmet Needs
13.3.4 U.K.
13.3.4.1 Market Size and Growth Potential
13.3.4.2 New Market Opportunities
13.3.4.3 Unmet Needs
13.3.5 France
13.3.5.1 Market Size and Growth Potential
13.3.5.2 New Market Opportunities
13.3.5.3 Unmet Needs
13.3.6 Italy
13.3.6.1 Market Size and Growth Potential
13.3.6.2 New Market Opportunities
13.3.6.3 Unmet Needs
13.3.7 Spain
13.3.7.1 Market Size and Growth Potential
13.3.7.2 New Market Opportunities
13.3.7.3 Unmet Needs
13.3.8 Russia
13.3.8.1 Market Size and Growth Potential
13.3.9 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 Key Dynamics
13.4.2 Competitive Landscape
13.4.3 China
13.4.3.1 Market Size and Growth Potential
13.4.3.2 New Market Opportunities
13.4.3.3 Unmet Needs
13.4.4 Japan
13.4.4.1 Market Size and Growth Potential
13.4.4.2 New Market Opportunities
13.4.4.3 Unmet Needs
13.4.5 India
13.4.5.1 Market Size and Growth Potential
13.4.5.2 New Market Opportunities
13.4.5.3 Unmet Needs
13.4.6 Australia
13.4.6.1 Market Size and Growth Potential
13.4.6.2 New Market Opportunities
13.4.6.3 Unmet Needs
13.4.7 South Korea
13.4.7.1 Market Size and Growth Potential
13.4.7.2 New Market Opportunities
13.4.7.3 Unmet Needs
13.4.8 Rest-of-APAC
13.5 Latin America
13.5.1 Key Dynamics
13.5.2 Brazil
13.5.2.1 Market Size and Growth Potential
13.5.2.2 New Market Opportunities
13.5.2.3 Unmet Needs
13.5.3 Mexico
13.5.3.1 Market Size and Growth Potential
13.5.3.2 New Market Opportunities
13.5.3.3 Unmet Needs
13.5.4 Rest-of-Latin America
13.6 Rest-of-the-World
13.6.1 Key Dynamics
13.6.1.1 New Market Opportunities
13.6.1.2 Unmet Needs
14 Company Profiles
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global RNA Sequencing Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Bio-Rad Laboratories, Inc.
14.3.1 Company Overview
14.3.2 Role of Bio-Rad Laboratories, Inc. in the Global RNA Sequencing Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 BGI
14.4.1 Company Overview
14.4.2 Role of BGI in the Global RNA Sequencing Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 F. Hoffmann-La Roche AG
14.5.1 Company Overview
14.5.2 Role of F. Hoffmann-La Roche AG in the Global RNA Sequencing Market
14.5.3 Financials
14.5.4 Key Insights About Financial Health of the Company
14.5.5 SWOT Analysis
14.6 Fluidigm Corporation
14.6.1 Company Overview
14.6.2 Role of Fluidigm Corporation in the Global RNA Sequencing Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Illumina, Inc.
14.7.1 Company Overview
14.7.2 Role of Illumina, Inc. in the Global RNA Sequencing Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 Lexogen GmbH
14.8.1 Company Overview
14.8.2 Role of Lexogen GmbH in the Global RNA Sequencing Market
14.8.3 SWOT Analysis
14.9 Oxford Nanopore Technologies
14.9.1 Company Overview
14.9.2 Role of Oxford Nanopore Technologies in the Global RNA Sequencing Market
14.9.3 SWOT Analysis
14.10 Pacific Biosciences
14.10.1 Company Overview
14.10.2 Role of Pacific Biosciences in the Global RNA Sequencing Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Dolomite Bio
14.11.1 Company Overview
14.11.2 Role of Dolomite Bio. in the Global RNA Sequencing Market
14.11.3 SWOT Analysis
14.12 Merck KGaA
14.12.1 Company Overview
14.12.2 Role of Merck KGaA in the Global RNA Sequencing Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 Becton, Dickinson and Company
14.13.1 Company Overview
14.13.2 Role of Becton, Dickinson, and Company in the Global RNA Sequencing Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 Takara Bio Inc.
14.14.1 Company Overview
14.14.2 Role of Takara Bio Inc. in the Global RNA Sequencing Market
14.14.3 Financials
14.14.4 Key Insights About Financial Health of the Company
14.14.5 SWOT Analysis
14.15 QIAGEN N.V.
14.15.1 Company Overview
14.15.2 Role of QIAGEN N.V. plc in the Global RNA Sequencing Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific in the Global RNA Sequencing Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
List of Tables
Table 4.1: Assessment of Existing Technologies in Global RNA Sequencing Market
Table 4.2: Key Commercialized Products Offered by Major Market Players
Table 5.1: Performance and Cost Comparison of Sequencing Platforms of Various Generations
Table 6.1: Cost comparison Analysis of Portable Sequencers
Table 8.1: Specifications of Available Instruments in the Market
Table 8.2: Respective Offerings of Key Players in Kits Segment
Table 8.3: Key Products (Kits and Reagents) Currently Offered by Key Market Players
List of Figures
Figure 1: Implications of RNA Sequencing
Figure 2: Cumulative Number of Genes Linked to Rare Diseases, 2010-2018
Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global RNA Sequencing Market
Figure 4: Global RNA Sequencing Market, by Product Type, 2018 vs. 2028 ($Million)
Figure 5: Global RNA Sequencing Market, by Technology, 2018 vs. 2028 ($Million)
Figure 6: Global RNA Sequencing Market, by Workflow, 2018 vs. 2028 ($Million)
Figure 7: Global RNA Sequencing Market, by End User, 2018 vs. 2028 ($Million)
Figure 8: Global RNA Sequencing Market, by Application, 2018 vs. 2028 ($Million)
Figure 9: Global RNA Sequencing Market Snapshot
Figure 2.1: Global RNA Sequencing Market Segmentation
Figure 3.1: Global RNA Sequencing Market Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: North America RNA Sequencing Market, 2018-2028
Figure 4.2: North America RNA Sequencing Market – Key Driving Factors & Impact
Figure 4.3: Europe RNA Sequencing Market, 2018-2028
Figure 4.4: Europe RNA Sequencing Market – Key Driving Factors & Impact
Figure 4.5: Asia-Pacific RNA Sequencing Market, 2018-2028
Figure 4.6: Asia-Pacific RNA Sequencing Market – Key Driving Factors & Impact
Figure 4.7: Latin America RNA Sequencing Market, 2018-2028
Figure 4.8: Latin America RNA Sequencing Market – Key Driving Factors & Impact
Figure 4.9: Rest-of-the-World RNA Sequencing Market, 2018-2028
Figure 4.10: Rest-of-the-World RNA Sequencing Market – Key Driving Factors & Impact
Figure 5.1: Global RNA Sequencing Market: Existing Patent Segmentation
Figure 5.2: NGS RNA Sequencing Publications (2009-2017)
Figure 6.1: Impact Analysis of Market Drivers and Restraints
Figure 6.2: Cost of Genome Sequencing 2010-2018
Figure 6.3: Global RNA Sequencing Market: Funding Scenario (FY2016-FY2019)
Figure 7.1: Key Developments and Strategies, 2016–2019
Figure 7.2: Product Launch and Upgradations (by Company), 2016–2019
Figure 7.3: Synergistic Activities (by Company), 2016 –2019
Figure 7.4: Funding and Expansions (by Company), 2016 –2019
Figure 7.5: Mergers and Acquisitions Share (by Company), 2016 –2019
Figure 7.6: Product Approvals Share (by Company), 2016 –2019
Figure 7.7: Market Share Analysis for the Global RNA Sequencing Market, 2018
Figure 7.8: Growth Share Matrix for Global RNA Sequencing Market (by Companies), 2018
Figure 8.1: Global RNA Sequencing Market (by Product Type)
Figure 8.2: Global RNA Sequencing Market (by Product Type), 2019 and 2028
Figure 8.3: Global RNA Sequencing Market for Instruments, 2018-2028
Figure 8.4: Global RNA Sequencing Market for Fully Automated Instruments, 2018-2028
Figure 8.5: Global RNA Sequencing Market for Semi-Automated Instruments, 2018-2028
Figure 8.6: Global RNA Sequencing Market for Reagents and Kits, 2018-2028
Figure 8.7: Global Sample Enrichment Reagent and Kits Market, 2018-2028
Figure 8.8: Global Sample Isolation, Extraction Reagent and Kits Market, 2018-2028
Figure 8.9: Global Library Preparation Reagent and Kits Market, 2018-2028
Figure 8.10: Global Sequencing Reagent and Kits Market, 2018-2028
Figure 8.11: Global RNA Sequencing Market for Software, 2018-2028
Figure 9.1: Global RNA Sequencing Market (by Technology), 2018-2028
Figure 9.2: Global RNA Sequencing Market for Single Molecule Based Sequencing Technology Segment, 2018-2028
Figure 9.3: Global RNA Sequencing Market for Sequence by Synthesis Technology Segment, 2018-2028
Figure 9.4: Global RNA Sequencing Market for Nanopore Sequencing Technology Segment, 2018-2028
Figure 9.5: Global RNA Sequencing Market for Ion Torrent Semiconductor Sequencing Technology Segment, 2018-2028
Figure 10.1: Global RNA Sequencing Market (by Workflow), 2019 and 2028
Figure 10.2: Global RNA Sequencing Market for Sample Isolation and Extraction, 2018-2028
Figure 10.3: Global RNA Sequencing Market for Sample Enrichment, 2018-2028
Figure 10.4: Global RNA Sequencing Market for Library Preparation, 2018-2028
Figure 10.5: Global RNA Sequencing Market for Sequencing, 2018-2028
Figure 10.6: Global RNA Sequencing Market for Data Analysis and Management, 2018-2028
Figure 11.1: Global RNA Sequencing Market (by End User)
Figure 11.2: Global RNA Sequencing Market (by End User), 2019 and 2028
Figure 11.3: Global RNA Sequencing Market for Biopharmaceuticals, 2018-2028
Figure 11.4: Global RNA Sequencing Market for Diagnostic Centers, 2018-2028
Figure 11.5: Global RNA Sequencing Market for Life-Sciences and Biotechnology Companies, 2018-2028
Figure 11.6: Global RNA Sequencing Market for Research and Academia, 2018-2028
Figure 12.1: Global RNA Sequencing Market (by Application), 2019 and 2028
Figure 12.2: Global RNA Sequencing Market for Diagnostics, 2018-2028
Figure 12.3: Global RNA Sequencing Market for Drug Discovery, 2018-2028
Figure 12.4: Global RNA Sequencing Market for Translational Medicine, 2018-2028
Figure 12.5: Global RNA Sequencing Market for Other Applications Market, 2018-2028
Figure 13.1: RNA Sequencing Market (by Region), 2019 and 2028
Figure 13.2: RNA Sequencing Market (by Region), 2018-2028
Figure 13.3: North America: Market Dynamics
Figure 13.4: North America RNA Sequencing Market, (by Country), 2018-2028
Figure 13.5: North America: Growth Strategies by Key Market Players, (2016-2019)
Figure 13.6: North America: Competitive Assessment of Key Market Players
Figure 13.7: U.S. RNA Sequencing Market), 2018-2028
Figure 13.8: Canada RNA Sequencing Market, 2018-2028
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe RNA Sequencing Market, (by Country), 2018-2028
Figure 13.11: Europe: Growth Strategies by Key Market Players, (2016-2019)
Figure 13.12: Europe: Competitive Assessment of Key Market Players
Figure 13.13: Germany RNA Sequencing Market, 2018-2028
Figure 13.14: U.K. RNA Sequencing Market, 2018-2028
Figure 13.15: France RNA Sequencing Market, 2018-2028
Figure 13.16: Italy RNA Sequencing Market, 2018-2028
Figure 13.17: Spain RNA Sequencing Market, 2018-2028
Figure 13.18: Russia RNA Sequencing Market, 2018-2028
Figure 13.19: Rest-of-Europe RNA Sequencing Market, 2018-2028
Figure 13.20: Asia-Pacific: Market Dynamics
Figure 13.21: Asia-Pacific RNA Sequencing Market, (by Country), 2018-2028
Figure 13.22: Asia-Pacific: Growth Strategies by Key Market Players, (2016-2019)
Figure 13.23: Asia-Pacific: Competitive Assessment of Key Market Players
Figure 13.24: China RNA Sequencing Market, 2018-2028
Figure 13.25: Japan RNA Sequencing Market, 2018-2028
Figure 13.26: India RNA Sequencing Market, 2018-2028
Figure 13.27: Australia RNA Sequencing Market, 2018-2028
Figure 13.28: South Korea RNA Sequencing Market, 2018-2028
Figure 13.29: Rest-of-APAC RNA Sequencing Market, 2018-2028
Figure 13.30: Latin America: Market Dynamics
Figure 13.31: Latin America RNA Sequencing Market, (by Country), 2018-2028
Figure 13.32: Brazil RNA Sequencing Market, 2018-2028
Figure 13.33: Mexico RNA Sequencing Market, 2018-2028
Figure 13.34: Rest-of-Latin America RNA Sequencing Market, 2018-2028
Figure 13.35: Rest-of-the-World: Market Dynamics
Figure 13.36: Rest-of-the-World RNA Sequencing Market, 2018-2028
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 14.9: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 14.10: Bio-Rad Laboratories, Inc.: Sales (by Segment), $Million, 2016-2018
Figure 14.11: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
Figure 14.12: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 14.13: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.14: BGI: Overall Product Portfolio
Figure 14.15: BGI: Overall Financials, 2017-2018
Figure 14.16: BGI: Sales (by Segment), 2017-2018
Figure 14.17: BGI: Sales (by Region), 2017-2018
Figure 14.18: BGI: R&D Expenditure, 2017-2018
Figure 14.19: BGI: SWOT Analysis
Figure 14.20: F. Hoffmann-La Roche AG: Overall Product Portfolio
Figure 14.21: F. Hoffmann-La Roche AG: Overall Financials, 2016-2018
Figure 14.22: F. Hoffmann-La Roche AG: Revenue (by Segment), $Million, 2016-2018
Figure 14.23: F. Hoffmann-La Roche AG: Revenue (by Region), 2016-2018
Figure 14.24: F. Hoffmann-La Roche AG: R&D Expenditure, 2016-2018
Figure 14.25: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 14.26: Fluidigm Corporation: Overall Product Portfolio
Figure 14.27: Fluidigm Corporation: Overall Financials, 2016-2018
Figure 14.28: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018
Figure 14.29: Fluidigm Corporation: Revenue (by Region), 2016-2018
Figure 14.30: Fluidigm Corporation: R&D Expenditure, 2016-2018
Figure 14.31: Fluidigm Corporation: SWOT Analysis
Figure 14.32: Illumina, Inc.: Overall Product Portfolio
Figure 14.33: Illumina, Inc.: Overall Financials, 2016-2018
Figure 14.34: Illumina, Inc.: Revenue (by Segment), $Million, 2016-2018
Figure 14.35: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 14.36: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 14.37: Illumina, Inc.: SWOT Analysis
Figure 14.38: Lexogen GmbH: Overall Product Portfolio
Figure 14.39: Lexogen GmbH: SWOT Analysis
Figure 14.40: Oxford Nanopore Technologies: Product Offerings
Figure 14.41: Oxford Nanopore Technologies: SWOT Analysis
Figure 14.42: Pacific Biosciences: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.43: Pacific Biosciences: Overall Financials, 2016-2018
Figure 14.44: Pacific Biosciences: Revenue (by Region), 2016-2018
Figure 14.45: Pacific Biosciences: R&D Expenditure, 2016-2018
Figure 14.46: Pacific Biosciences: SWOT Analysis
Figure 14.47: Dolomite Bio.: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.48: Dolomite Bio.: SWOT Analysis
Figure 14.49: Merck KGaA: Existing Product Offerings in the Global RNA Sequencing Market
Figure 14.50: Merck KGaA: Overall Financials, 2016-2018
Figure 14.51: Merck KGaA: Revenue (by Segment), $Million, 2016-2018
Figure 14.52: Merck KGaA: Revenue (by Region), 2016-2018
Figure 14.53: Merck KGaA: R&D Expenditure, 2016-2018
Figure 14.54: Merck KGaA: SWOT Analysis
Figure 14.55: Beckton, Dickinson and Company: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.56: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 14.57: Becton, Dickinson and Company: Revenue (by Business Segment), 2017-2019
Figure 14.58: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019
Figure 14.59: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 14.60: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 14.61: Becton, Dickinson and Company: SWOT Analysis
Figure 14.62: Takara Bio Inc.: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.63: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 14.64: Takara Bio Inc.: Revenue (by Segment), 2017-2019
Figure 14.65: Takara Bio Inc.: Revenue (by Region), 2017-2019
Figure 14.66: Takara Bio Inc.: R&D Expenditure, 2017-2019
Figure 14.67: Takara Bio Inc.: SWOT Analysis
Figure 14.68: QIAGEN N.V.: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.69: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 14.70: QIAGEN N.V.: Revenue (by Segment), $Million, 2016-2018
Figure 14.71: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 14.72: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 14.73: QIAGEN N.V.: SWOT Analysis
Figure 14.74: Thermo Fisher Scientific Inc.: Existing Product Offerings in Global RNA Sequencing Market
Figure 14.75: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 14.76: Thermo Fisher Scientific Inc: Sales (by Segment), $Billion, 2016-2018
Figure 14.77: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
Figure 14.78: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 14.79: Thermo Fisher Scientific Inc.: SWOT Analysis
LOADING...
FEATURED COMPANIES
- BGI
- Dolomite Bio
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- Illumina, Inc.
- Lexogen GmbH
- MORE
According to the market intelligence report titled “Global RNA Sequencing Market- Analysis and Forecast, 2019-2028”, the global RNA sequencing market was valued at $976.1 million in 2018 and is anticipated to grow over $3,521.0 million by 2028. The global RNA sequencing market is expected to grow at double-digit compound annual growth rate in the forecast period 2019-2028, aided primarily by the impressive growth in the manufacturing market.
RNA sequencing has emerged as one of the most promising techniques in the field of genomics. It is a recent technique that emerged after the invention of next-generation sequencing. Earlier, Sanger sequencing techniques and microarray-based methods were used for genome analysis. Compared with the earlier methods, RNA sequencing offers a combination of higher coverage and greater resolution for the analysis of the transcriptome. Current advancements in the RNA sequencing workflow, including sample preparation, sequencing instruments, and data analysis software, among others, has significantly provided unprecedented opportunities for executing transcriptome profiling.
According to Nitish Singh, Analyst, “North America is the leading contributor in the RNA sequencing market and contributed approximately 41.65% to the global market value in 2018. This region is anticipated to grow at a CAGR of 14.16% during the forecast period 2019-2028 and continue dominating the global market in 2028 as well. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 14.59% during the forecast period from 2019-2028. The European region also contributed a significant share of 28.40% to the global market and is anticipated to grow at a CAGR of 14.25% during the forecast period from 2019-2028.”
Research Highlights:
Sequence by synthesis technology is expected to witness a robust CAGR of 14.31% during the forecast period 2019-2028. However, the RNA sequencing market for reagents and kits is anticipated to witness the growth of 14.49% during the forecast period 2019-2028.
Illumina, Inc., is currently the largest shareholder in the global RNA sequencing market. This market dominance is attributed to the company’s presence within the market through its dedicated product mix for RNA sequencing.
This market intelligence report provides a multi-dimensional view of the global RNA sequencing market in terms of market size and growth potential. This research report aims at answering various aspects of the global RNA sequencing market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and upgradations, approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of product sales, manufacturers, and trend analysis by segment, market share, and growth-share analysis by companies. Additionally, the report provides a comprehensive, attractive analysis and opportunity analysis for the entire RNA sequencing market for 2018 and 2028.
This report is a meticulous compilation of research on more than 25 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 20 leading and emerging companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BGI, F. Hoffmann La-Roche AG, Fluidigm Corporation, Illumina, Inc., Lexogen GmbH, Oxford Nanopore Technologies, Pacific Biosciences, QIAGEN N.V., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Dolomite Bio, Takara Bio Inc., and Merck KGaA.
The answers to the following key questions can be derived from this report:
- What are the major market drivers, restraining factors, and opportunities in the global RNA sequencing market?
- What are the underlying structures resulting in the emerging trends within the global RNA sequencing market?
- What are the key development strategies which are incorporated by the major players in order to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for RNA sequencing?
- What are the key patents obtained by the companies for various technologies in the global RNA sequencing market?
- How each segment of the market is anticipated to grow during the forecast period 2019 to 2028 and what is the estimated revenue to be generated by each of the segments on the basis of:
- product type, including types of instruments, reagents, and kits, and software
- technology, including, single-molecule-based sequencing, sequence by synthesis technology, nanopore sequencing technology, and ion torrent sequencing technology
- workflow, including sample enrichment, nucleic acid isolation and extraction, library preparation, sequencing, and data analysis and management
- end user, including biopharmaceuticals, life science and biotechnology companies, diagnostic centers, and research and academia
- applications, including drug discovery, translational medicine, diagnostics, and others
- region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World
- Who are the leading players with significant offering to the global RNA sequencing market? What is the anticipated market dominance for each of these leading players?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the challenges in the global RNA sequencing market currently?
Key trends targeted in the report:
- What are the emerging trends in the global RNA sequencing market?
- Which companies are anticipated to be highly disruptive in the future and why?
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- BGI
- F. Hoffmann-La Roche AG
- Fluidigm Corporation
- Illumina, Inc.
- Lexogen GmbH
- Oxford Nanopore Technologies
- Pacific Biosciences
- Dolomite Bio
- Merck KGaA
- Becton, Dickinson, and Company
- Takara Bio Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
